A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence

Overview of attention for article published in Clinical Epigenetics, December 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 32,486 followers.

RT @Aiims1742: Continuing the generally disappointing trend of epigenetic therapies (DNMT & HDAC inh) in advanced #PancreaticCancer, here’s…

RT @Aiims1742: Continuing the generally disappointing trend of epigenetic therapies (DNMT & HDAC inh) in advanced #PancreaticCancer, here’s…

RT @Aiims1742: Continuing the generally disappointing trend of epigenetic therapies (DNMT & HDAC inh) in advanced #PancreaticCancer, here’s…

RT @Aiims1742: Continuing the generally disappointing trend of epigenetic therapies (DNMT & HDAC inh) in advanced #PancreaticCancer, here’s…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.